Collegium Pharmaceutical

Collegium Pharmaceutical

COLL· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +61.6% in FY2025

Vikram Karnani is the CEO of Collegium Pharmaceutical and was paid $1.7M in FY2025 (Dec), down 84%.

Pay$100 in the stock at the end of FY21 → $248
CEO pay is from each Collegium Pharmaceutical proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives6

See all
  1. 1David DieterFY2025
  2. 2Colleen TupperFY2025
  3. 3Scott DreyerFY2025
  4. 4Shirley KuhlmannFY2025
  5. 5Thomas Smith, M.D.FY2025
  6. 6Vikram KarnaniFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Collegium Pharmaceutical paid its 6 named executives $17.4M in total in FY2025 (Dec). CEO Vikram Karnani was paid $1.7M of that.

Name
David DieterExecutive Vice President and General Counsel
Colleen TupperExecutive Vice President and Chief Financial Officer
Scott DreyerExecutive Vice President and Chief Commercial Officer
Shirley KuhlmannFormer Executive Vice President, Chief Administrative Officer, General Counsel and Secretary
Thomas Smith, M.D.Executive Vice President and Chief Medical Officer
Vikram KarnaniPresident and Chief Executive Officer

of each named executive, from the Summary Compensation Table of each proxy.

Peers18

See all

The FY2024 (Dec) proxy of Collegium Pharmaceutical names 18 peer companies for pay. Pay versus performance data of Collegium Pharmaceutical for that year is not on file, so it has no rank.

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Activity

  1. Pay
    Collegium Pharmaceutical CEO pay fell 84% to $1.7M. The stock rose 62% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Collegium Pharmaceutical General counsel pay fell 16% to $2.8M. The stock rose 62% in FY2025 (Dec).
    DEF 14A
  3. Pay
    Collegium Pharmaceutical CFO pay rose 10% to $3.5M. The stock rose 62% in FY2025 (Dec).
    DEF 14A
  4. Pay
    Collegium Pharmaceutical Division head pay rose 22% to $2.5M. The stock fell 7% in FY2024 (Dec).
    DEF 14A
  5. Pay
    Collegium Pharmaceutical General counsel pay rose 15% to $3.3M. The stock fell 7% in FY2024 (Dec).
    DEF 14A
  6. Pay
    Collegium Pharmaceutical President pay rose 17% to $10.7M. The stock fell 7% in FY2024 (Dec).
    DEF 14A
  7. Pay
    Collegium Pharmaceutical CFO pay rose 17% to $3.2M. The stock fell 7% in FY2024 (Dec).
    DEF 14A
  8. Pay
    Collegium Pharmaceutical Division head pay rose 241% to $2.0M. The stock rose 33% in FY2023 (Dec).
    DEF 14A
  9. Pay
    Collegium Pharmaceutical General counsel pay rose 18% to $2.9M. The stock rose 33% in FY2023 (Dec).
    DEF 14A
  10. Pay
    Collegium Pharmaceutical Division head pay rose 18% to $2.6M. The stock rose 33% in FY2023 (Dec).
    DEF 14A
  11. Pay
    Collegium Pharmaceutical President pay rose 32% to $9.1M. The stock rose 33% in FY2023 (Dec).
    DEF 14A
  12. Pay
    Collegium Pharmaceutical CFO pay rose 18% to $2.7M. The stock rose 33% in FY2023 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AApr 7, 2026FY2025
Annual report10-KFeb 26, 2026FY2025
Proxy statementDEF 14AMar 28, 2025FY2024
Annual report10-KFeb 27, 2025FY2024
Proxy statementDEF 14AApr 5, 2024FY2023
Annual report10-KFeb 22, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data